Changelog — 2026-02-18
2026-02-18
O
ONON
On Holding AG
Status: RECRUITING → SUSPENDED (The trial is currently paused during a move to a new institu) — EARLY_PHASE1
NCT05829655
• Early_Phase 1 • Status: Recruiting → Suspended • Why stopped: The trial is currently paused during a move to a new institution and acquisition of the new IRB approval at University o…
🚩 MAJOR
2026-02-18
ABBV
AbbVie Inc.
Primary endpoint added: Percentage of Participants With a Grade 0 or 1 and a ≥ 2-grade Improvement From Baseline on the FWS According to Both Investigator and Subject Assessments of Glabellar Lines (GL) Severity at Maximum Frown at Day 7 [US FDA] — PHASE3
NCT05248880
• Phase 3
MEDIUM
2026-02-18
PFE
PFIZER INC
Enrollment 400→412 (3%) — PHASE3
NCT05911295
• Phase 3 • Enrollment 400→412 (+3%)
MEDIUM
2026-02-18
MRK
Merck & Co., Inc.
Enrollment 390→326 (-16%) — PHASE2
NCT03742895
• Phase 2 • Enrollment 390→326 (-16%)
MEDIUM
2026-02-18
AZN
ASTRAZENECA PLC
Enrollment 55000→52121 (-5%)
NCT06355934
• Enrollment 55000→52121 (-5%)
MEDIUM
2026-02-18
V
VRDN
Viridian Therapeutics, Inc.\DE
Status: ACTIVE_NOT_RECRUITING → COMPLETED — PHASE3
NCT06384547
• Phase 3 • Status: Active, not recruiting → Completed
MEDIUM
2026-02-18
A
AMPL
Amplitude, Inc.
Enrollment 120→115 (-4%) — NA
NCT06457685
• Na • Enrollment 120→115 (-4%)
MEDIUM
2026-02-18
BMY
BRISTOL MYERS SQUIBB CO
Enrollment 117→147 (26%) — PHASE1
NCT06121843
• Phase 1 • Enrollment 117→147 (+26%)
MEDIUM
2026-02-18
I
IMVT
Immunovant, Inc.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT05517447
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-18
VTRS
Viatris Inc
Status: NOT_YET_RECRUITING → RECRUITING — PHASE3
NCT07201129
• Phase 3 • Status: Not yet recruiting → Recruiting
MEDIUM
2026-02-18
D
DNTH
Dianthus Therapeutics, Inc. /DE/
Locations updated — PHASE3
NCT06858579
• Phase 3
MEDIUM
2026-02-18
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT06787612
• Phase 2
MEDIUM
2026-02-18
ABBV
AbbVie Inc.
Primary endpoint added: Number of Participants with Adverse Events (AEs) — PHASE3
NCT04161898
• Phase 3
MEDIUM
2026-02-18
SNY
Sanofi
Enrollment 1630→1714 (5%) — PHASE3
NCT06736041
• Phase 3 • Enrollment 1630→1714 (+5%)
MEDIUM
2026-02-18
O
ONON
On Holding AG
Enrollment 24→27 (12%) — NA
NCT04054050
• Na • Enrollment 24→27 (+12%)
MEDIUM
2026-02-18
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE4
NCT07221838
• Phase 4
MEDIUM
2026-02-18
AZN
ASTRAZENECA PLC
Enrollment 60→12 (-80%) — PHASE2
NCT05137262
• Phase 2 • Enrollment 60→12 (-80%)
MEDIUM
2026-02-18
A
ALC
ALCON INC
Enrollment 161→188 (17%) — NA
NCT06444516
• Na • Enrollment 161→188 (+17%)
MEDIUM
2026-02-18
MRK
Merck & Co., Inc.
Primary endpoint added: Maximum Concentration (Cmax) of DOR Following Once-Daily Dosing in Plasma at Steady-State — PHASE2
NCT04375800
• Phase 2
MEDIUM